lapatinib (Tykerb)
Jump to navigation
Jump to search
Indications
- adjunct treatment of breast cancer
- used in combination with capecitabine[1]
Dosage
Monitor
- liver function tests (serum ALT, serum AST, serum bilirubin, serum alkaline phosphatase) baseline, then every 4-6 weeks & as clinically indicated[2]
Adverse effects
- somewhat difficult to assess given the patient popluation & other treatments
- most common: diarrhea, dyspepsia, rash
- hepatoxicity[2]
Mechanism of action
- small-molecule tyrosine kinase inhibitor of HER1 & HER2
- antineoplastic activity in patients with HER2-positive metastatic breast cancer, including inflammatory breast cancer
More general terms
Additional terms
References
- ↑ 1.0 1.1 Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006 Dec 28;355(26):2733-43. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17192538
- ↑ 2.0 2.1 2.2 Prescriber's Letter 17(7): 2010 Recommended Lab Monitoring for Common Medications Liver Function Test Scheduling Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=260704&pb=PRL (subscription needed) http://www.prescribersletter.com